Active prophylaxis for RSV: state of art

Anna C Vittucci, Paola Zangari, Claudia Ciarlitto, Chiara Di Camillo, Annalisa Grandin, Nicola Cotugno, Maria R Marchili, Alberto Villani

Research output: Contribution to journalArticle


Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children but represents also an important cause of morbidity in adults, particularly in the elderly and immunocompromised persons. Despite its global impact on human health, no effective treatment is available except for supportive care and no safe vaccine has been still licensed. Vaccine development has been hindered by several factors including vaccine enhanced disease associated with formalin-inactivated RSV vaccine, ethical concerns and lack of consensus concerning the most appropriate target antigen. In this review, we analyze history of RSV vaccine and current approaches for preventing RSV including live-attenuated, vector-based, subunit, nucleic acid-based, particle based vaccines and we debate about concerns on target population, correlates of protection and obstacles that are slowing the progress toward a successful RSV vaccination strategy.

Original languageEnglish
JournalMinerva Pediatrica
Publication statusE-pub ahead of print - Oct 18 2018

Fingerprint Dive into the research topics of 'Active prophylaxis for RSV: state of art'. Together they form a unique fingerprint.

  • Cite this

    Vittucci, A. C., Zangari, P., Ciarlitto, C., Di Camillo, C., Grandin, A., Cotugno, N., Marchili, M. R., & Villani, A. (2018). Active prophylaxis for RSV: state of art. Minerva Pediatrica.